Assessing Cognitive fUnction and MEasuring the Cerebral circulatioN on HaemoDialysis (ACUMEN-HD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02393222|
Recruitment Status : Unknown
Verified March 2015 by NHS Greater Glasgow and Clyde.
Recruitment status was: Not yet recruiting
First Posted : March 19, 2015
Last Update Posted : March 19, 2015
Stroke disease and cognitive impairment are common in patients established on haemodialysis (HD) for end-stage renal disease (ESRD). Further, initiation of HD appears to transiently increase the risk of stroke. The mechanism by which this occurs is not known.
Using ultrasound, patient questionnaires and brain MRI our study will observe changes in cognition and cerebral blood flow whilst receiving HD compared to a non-dialysis day. Transient clinical and ultrasound alterations will be correlated to radiographic changes in cerebral perfusion and structure on MRI to determine the underlying mechanism for the increased stroke risk. The investigators will observe this effect in the immediate and longer term (12 months observation).
A greater understanding will allow development of effective preventive strategies.
|Condition or disease||Intervention/treatment|
|End-Stage Renal Disease Stroke Cognition Disorders||Other: Observing effect of routine HD|
Stroke is common in the United Kingdom and a leading cause of adult disability. It has been reported that more than half of all stroke survivors remain dependent on carers for everyday activities. A greater understanding stroke disease has led to improvements in stroke care for the general population.
Patients with ESRD are at increased risk of cerebrovascular disease with a risk approximately 5-10 times higher than the general population yet a relative paucity of data exploring the mechanisms and impact of stroke disease on patients on HD remains. Signs of cerebrovascular disease are common with evidence of early stroke disease (white matter hyperintensities on MRI) having been described in up to 50% of ESRD patients. In addition to this it is now estimated that up to 70% of patients on dialysis aged 55 years and older have moderate to severe cognitive impairment. Previous work has revealed that cognition declines during dialysis - specifically a decrease in executive function has been reported, without significant memory impairment. Such findings are in suggestive of vascular related injury. Mean cerebral blood flow assessed by transcranial Doppler ultrasound is reduced during dialysis, although whether this finding is associated with a clinical outcome is not clear.
In order to generate appropriate preventive strategies for stroke in ESRD the mechanism by which injury occurs must be confirmed. In addition, although a decrease in executive function has been shown during HD it is unclear if long-term HD is associated with progressive decline or if this clinical finding correlates with neuroimaging.
This study is being performed to determine:
- The impact of long term HD (including indices of cardiovascular instability) on changes on brain MRI and cognitive function.
- The relationship between intracerebral blood flow rate, brain MRI findings and neurocognitive function
- The relationship between intracranial blood flow measures (during and post haemodialysis (HD)) and brain perfusion and structure
Following informed written consent patients will be observed over a 12 month period. On the first visit participants will undergo a transcranial ultrasound before and during HD to achieve baseline and intra-dialytic blood flow velocities. During the dialysis sessions a neurocognitive assessment (patient questionnaire) will be performed which will assess multiple cognitive domains. On completion of dialysis a subgroup will undergo a brain MRI. All patients will meet with the investigators within 2 weeks to repeat the neurocognitive assessment on a non-dialysis day. This will allow for comparison of cognitive changes, alterations in cerebral blood flow and (in some) correlation with MRI findings. All participants will repeat this process 12 months later.
|Study Type :||Observational|
|Estimated Enrollment :||97 participants|
|Official Title:||Exploring the Natural History of Cerebrovascular Disease in Patients With End-stage Renal Disease on Haemodialysis|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||August 2017|
Patients with ESRD on HD
Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
Other: Observing effect of routine HD
Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
- Progression of white matter hyperintensities on MRI [ Time Frame: 12 months ]Use of visual rating scales to quantify white matter burden at time 0 and 12 months
- Correlation between alterations in cerebral blood flow and cognition [ Time Frame: Within 4 hour treatment period (of HD) ]Statistical correlation determined between a decreased in cerebral blood flow (as measured on transcranial doppler) and reduction in cognitive scores on assessment
- Correlation between alterations in cerebral blood flow and white matter hyperintensity burden progression [ Time Frame: 12 months ]Statistical correlation between reductions in cerebral bloe
- Evidence of transient cognitive impairment during HD [ Time Frame: Within 2 weeks (direct comparison of cognition during dialysis and on non-dialysis day) ]Use of multi-domain neurocognitive battery to assess cognition during HD. Baseline cognition will be assessed on a non-dialysis day.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02393222
|Contact: Mark D Findlay, MBChBfirstname.lastname@example.org|
|Contact: Patrick B Mark, MBChB PhD||0141 email@example.com|
|Principal Investigator:||Mark D Findlay, MBChB||University of Glasgow|